Table 2.
Baseline characteristics of CAD patients in CAC culture study
| All patients (n = 6) | ||
|---|---|---|
| Medication (%) | ||
| Platelet inhibitors | 100 | |
| ACE inhibitors/ARBs | 100 | |
| β-blockers | 100 | |
| Statins | 100 | |
| Clinical characteristics | ||
| Age (years) | 66 ± 5 | |
| Male gender (%) | 83 | |
| Active smoking (%) | 17 | |
| Positive family history (%) | 17 | |
| Hyperlipidaemia (%) | 83 | |
| Arterial hypertension (%) | 100 | |
| Systolic BP (mmHg) | 183 ± 16 | |
| Diastolic BP (mmHg) | 88 ± 12 | |
| LV ejection fraction (%) | 64 ± 7 | |
| Affected coronaries (n) | 2.5 ± 0.2 | |
| Body mass index (kg·m−2) | 32 ± 3.3 | |
| Type II diabetes | ||
| Clinical chemistry | No (n = 3) | Yes (n = 3) |
| Fasting glucose (mmol L−1) | 5.9 ± 0.3 | 11.2 ± 2.9 |
| Total cholesterol (mmol L−1) | 5.4 ± 0.5 | 4.6 ± 0.5 |
| HDL cholesterol (mmol L−1) | 1.0 ± 0.1 | 1.0 ± 0.1 |
| LDL cholesterol (mmol L−1) | 3.8 ± 0.6 | 2.8 ± 0.4 |
| Triglycerides (mmol L−1) | 1.9 ± 0.8 | 2.0 ± 0.3 |
| Creatinin (mg·L−1) | 13.6 ± 3 | 12.1 ± 4 |
| Haemoglobin (mg·L−1) | 133 ± 6 | 131 ± 15 |
| Leukocytes (nL−1) | 7.4 ± 1.0 | 7.4 ± 1.8 |
| C-reactive protein (mg·L−1) | 6.4 ± 2.1 | 9.1 ± 6.1 |